LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

This recieved frim Peter Shearlock's stock pickes this morning...

Provexis a steal at under £10 million

The harsh treatment meted out to AIM stocks in the past six months has one positive aspect: it gives incoming investors a second chance to climb aboard interesting stocks at bargain basement levels. Provexis, the life sciences business that is developing food and dietary supplements, is a case in point. Its shares touched 5.5p in the summer. Today they are back to 2.38p – which is where they were before a couple of breakthrough deals were announced with multinationals to commercialise Provexis’ technology. The company is now valued at just £9.5 million. That is option money in the context of where Provexis could be in a few years’ time.

Provexis’ flagship technology is in a food supplement called Fruitflow which helps combat thrombosis and improves heart health. The company is looking to commercialise Fruitflow in four areas: food and dairy products, beverages, products for deep vein thrombosis, and dietary supplements and medical products. In the past year it has tied up a deal with Unilever, the giant food and household products business, to develop Fruitflow for the global spreads market. In November last year, it announced a similar deal with Coca-Cola for the beverages market.

They say you can judge people by the company they keep. Provexis is certainly moving in the right circles and there is every chance of more deals with top names in the current year. Fruitflow will also enter human trials aimed at furthering claims for the product in countering deep vein thrombosis this year. A second technology, for combating Crohn’s disease, is similarly entering human trials.

There is a more focused feel to Provexis since the former commercial director, Stephen Moon, took over as chief executive 18 months ago. He in turn brought in a new finance director last year. A business selling Fruitflow in a drink called Sirco has been closed down and the rights transferred to a third party. Provexis is now concentrating on developing its food and dietary technologies and finding new ones it can add to the pipeline. Two new people have been added to the research team.

At the last count, Provexis still had just over £1 million in the bank, having raised £1.86 million net in a placing last April. The next figures should show a reduced cash burn following the exit from Sirco and other restructuring moves.

The pull-back in the Provexis share price over the autumn and winter represents a tremendous opportunity to buy into a business that is just on the verge of commercialising its technology – and where the upside is huge. If you have the patience to stay with this one for a two or three-year haul it should reward you handsomely. Buy.

Anybody have any ideas on the 6% rise today? Thanks in advance.

No idea blanche - but long may it last! Almost forgot I hold a few of these... time it woke up.

Blanche / Toya

It was caused by the takeover bid for Angle (AGL) who are PXS's founders.

They were up almost 60% yesterday.

My post from ADVFN:-


outlook123 - 8 Apr'08 - 00:07 - 4006 of 4006 edit

It'll be very interesting to see if Andrew Newland is tempted by the increased offer for Angle and to find out who the bidder is.

My best guess would be IP Group, unless someone is after their stake in PXS with their remaining investments thrown in for free...........!

Clearly, yesterday's buying of PXS is no coincidence, so a definite hold and 'watch this space'.


P.S. Just learnt that Red Bull are about to launch a niche / premium cola, so hopefully Coca Cola won't be resting on their laurels for too long..................

http://www.bevnet.com/news/2008/03-24-2008-red_bull_cola.asp

Many thanks outlook 123!

http://telegraph.uk-wire.com/cgi-bin/articles/200808011632205045A.html?epic=PXS

The SP will take a hit on the dilution but this could present a great buying opportunity for anyone considering a high risk / high reward investment IMHO.

Heavy buying today, possibly ahead of good news from the one year Coca Cola trials which end mid-Nov.

ridiculous......happy but confused as to what action if any to take...

results out on tuesday according to their website, should make interesting reading and hopefully contain news on agreements....

2 RNSs today... here's one of them....looks as though there's life in PXS afterall.. it's looking much better !

ANYONE STILL IN ?


EXTENSION OF EXCLUSIVE FRUITFLOW TECHNOLOGY ASSESSMENT AGREEMENT WITH THE COCA-COLA COMPANY




Provexis plc (PXS.L), which discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, announces the extension of its exclusive technology assessment agreement for its patented Fruitflow anti-thrombotic technology with The Coca-Cola Company until 31 March 2009.




The exclusivity agreement covers all beverages, with the exception of mini-drinks. During the assessment period both parties will continue a programme of work including commercial and regulatory assessment.

More food news this morning

PROVEXIS PLC




('Provexis' or the 'Company')




Sirco launch




Provexis plc, the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, is pleased to announce the imminent launch by a license partner of the Sirco pure juice brand, containing the Company's Fruitflow anti-thrombotic technology.




The transfer by the Company of the Sirco brand to Multiple Marketing Limited in November 2007 included a non-exclusive license for the use of the Fruitflow anti-thrombotic product.




The new Sirco pure juice brand is due to be listed in most larger Waitrose stores from March 2009 and will be supported by a programme of promotional activity. Provexis understands that Multiple Marketing are progressing discussions with other major UK retailers, wholesalers and foodservice customers.




Multiple Marketing Limited is part of the R. M. Curtis group of companies that owns the Eat Natural cereal bar and Sunmagic fruit juice brands.




Stephen Moon, Chief Executive of Provexis plc said:




'We are confident that the functional heart health claims supporting our Fruitflow technology will appeal to consumers. We are pleased to be working with Multiple Marketing, a proven and successful brand owner, to exploit the opportunity.'

Looking a bit more optimistic. If they can clinch a deal with Coca-Cola then their future ought to be secured but of course anything can happen, especially these days! It does look promising though. Still holding a small amount.

IMHO the 29% stake acquired by DSM last Aug. was a 'game changer' for PXS.

I genuinely believe they are an easy ten bagger from this point.

.

Pinched off another bb.

Daily express May 08 2009, page 64:-
"Unilevers new ideas to pump up volume."
In article it mentions
"Unilever is also planning a major drive on healthy margarines and spreads"
It then goes on to say
"Butter should carry a health warning like cigarettes, said Polman.
"It is a major cause of cardio vascular disease."
-------------------------------------------------------------------------------Now that suggests to me that Univlever is still working with Provexis to enable their planning for a major drive on healthy margarines and spreads, and on the tubs it will say contains fruitflow that helps protect against major causes of cardio vascular diseases. IMHO
Now for Provexis to support the massive market of Unilever you would need a lot of tomatoes to make that concentrated Fruitflow.
Article also mentions Unilever "Has begun buying "sustainable" tomatoes from areas where they do no environmental damage"
Similar environmental message on side of Sirco cartoon.
So, IMHO, Unilever could still be planning to work with Provexis.

thanks Blanche, that's actually very good news - especially if they are already buying the source ingredients....posted the link over on the PXS board on iii which is very active if a little irreverent.

cheers

IMHO we could be awaiting a double-whammy announcement confirming a tie-up with Coke and Unilever.

Agreed that iii board has too much o/t chatter.

Please feel free to contribute to the ADVFN thread.

European Health Claim Adoption for Fruitflow (Provexis)


TIDMPXS

RNS Number : 9135S
Provexis PLC
28 May 2009

?
28 May 2009


PROVEXIS PLC


("Provexis" or the "Company")


European Health Claim Adoption for Fruitflow


Provexis plc, the life-science business that discovers, develops and licenses
scientifically-proven functional food, medical food and dietary supplement
technologies, is pleased to announce the adoption of scientific substantiation
of a health claim for the Company's Fruitflow anti-thrombotic technology by the
European Food Safety Authority ("EFSA").


The European Commission has introduced regulation aimed at harmonizing and
approving nutrition and health claims on foods. EFSA intends to establish an
EU-wide list of permitted claims by 2010 and health claims which do not comply
will be prohibited. Provexis submitted a health claim dossier in late 2008 under
Article 13(5) which regulates newly developed science or claims with proprietary
data.


Following a review by the EFSA panel, it was judged that a cause and effect
relationship has been established between consumption of Fruitflow and the
reduction of platelet aggregation in humans. EFSA has now adopted the scientific
opinion substantiating the health claim and this will go through the final
authorization procedure in the coming weeks.


Stephen Moon, Chief Executive of Provexis plc said:


"We understand that Fruitflow is the first technology to have a health claim
adopted by EFSA under Article 13(5) of the new legislation. While the process
has required intensive resource allocation over the last few months, we are
supportive of the new framework, given it clears the way for
scientifically-substantiated products to prevail in the market. This is a major
milestone for Provexis and one which we believe will have a very positive effect
on current and future commercial negotiations. It is also recognition of the
quality of our business, its technologies and our scientific and regulatory
capabilities."


ENQUIRIES


Provexis plcTel.01753 752 290
Stephen Moon, CEO
Steven Morrison, COO


ArbuthnotTel.020 7012 2000
Tom Griffiths
Alasdair Younie








END

Here we go then this is gr8t news. helps to pave the way for products into the market.

Yep,..looking good to recover my 3.65p entry level from a few years back..then push on from there...for starters 8p may well be on the cards soon ! (imho)